Physicians should not prescribe ADD drugs to healthy people

Physicians in Canada should consider refusing to prescribe cognitive enhancement medications—also used to treat attention deficit disorder (ADD)—to healthy patients, states an analysis article in CMAJ (Canadian Medical Association Journal). Lack of evidence for benefits and possibility of harm, limited health care resources and professional integrity of physicians are reasons why this use is not acceptable.

Prescription stimulants such as methylphenidate and dextroamphetamine are often used by people for "cognitive enhancement" to increase focus, concentration and memory. Because these drugs are available in Canada by prescription only, people must request them from their doctors.

"Physicians are important stakeholders in this debate, given the risks and regulations of prescription drugs and the potential for requests from patients for cognitive enhancers," writes Dr. Eric Racine, Institut de recherches cliniques de Montréal and Université de Montréal, with coauthors.

People take prescription stimulants to perform better in school or at work. Prevalence rates of cognitive enhancer use by university students ranges from 1% to 11% in some studies. Risks to taking stimulants include cardiovascular harm, dependence and psychosis. Current evidence has not shown that the desired benefits of enhanced are achieved with these substances.

"With uncertain benefits and clear harms, it is difficult to support the notion that physicians should prescribe a medication to a healthy individual for enhancement purposes," adds Dr. Racine with Cynthia Forlini, two coauthors of the paper.

Because physicians in Canada provide prescriptions through a publicly funded health care system with expanding demands for care, prescribing cognitive enhancers may not be an appropriate use of resources.

"Given the current state of limited evidence on medical, scientific, social and ethical aspects of cognitive enhancement, we call for greater attention to its appropriateness within existing Canadian health care systems," the authors conclude.

More information: Paper: www.cmaj.ca/lookup/doi/10.1503/cmaj.121508

add to favorites email to friend print save as pdf

Related Stories

Time to address stimulant abuse on our campuses

Sep 06, 2011

Universities and colleges need to do more to protect young adults from the dangers of illicit stimulant use and to educate them about harms, argue the authors of an editorial in CMAJ (Canadian Medical Association Journal).

Prescriptions for teens and young adults on the rise

Nov 29, 2010

Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have ...

Recommended for you

Using computers to design drugs

57 minutes ago

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

5 hours ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

18 hours ago

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments